Quest for the ideal cancer biomarker: An update on progress in capture and characterization of circulating tumor cells

Drug Development Research

Volumn 74, Issue 2, 2013, Pages 138-147

  Harris, Jennifer L ^a   Stocum, Michael ^b,c   Roberts, Lisa ^c   Jiang, Chunsheng ^c   Lin, Jessie ^c   Sprott, Kam ^c  

^a Pivot Oncology Consulting   (United States)

^b LABORATORY FOR MOLECULAR MEDICINE   (United States)

^c On Q ity   (United States)

Author keywords

biomarkers; cancer diagnosis; circulating tumor cells; metastasis; prognosis

Indexed keywords

ARSENIC TRIOXIDE; BRENTUXIMAB VEDOTIN; BUSULFAN; CAPECITABINE; CETUXIMAB; CISPLATIN; CRIZOTINIB; DASATINIB; DENILEUKIN DIFTITOX; EFUDUX; ERLOTINIB; EVEROLIMUS; EXEMESTANE; FLUOROURACIL; FULVESTRANT; GEFITINIB; IMATINIB; IRINOTECAN; LAPATINIB; LENALIDOMIDE; LETROZOLE; MERCAPTOPURINE; NILOTINIB; PANITUMUMAB; PERTUZUMAB; PURINTOL; RASBURICASE; TABLOID; TAMOXIFEN CITRATE; TIOGUANINE; TOSITUMOMAB I 131; TUMOR MARKER; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BREAST CANCER; CANCER GROWTH; CANCER PROGNOSIS; CIRCULATING TUMOR CELL; COLORECTAL CANCER; GASTROINTESTINAL STROMAL TUMOR; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; KIDNEY CARCINOMA; LEUKEMIA; LUNG NON SMALL CELL CANCER; LYMPHOMA; METASTASIS; MULTIPLE MYELOMA; PANCREAS CANCER; REVIEW; SOLID TUMOR; TREATMENT RESPONSE;

EID: 84875370011     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.21072     Document Type: Review

References (49)

1. Admon A,. 2011. Is proteomics starting to deliver on biomarkers discovery. Pigment Cell Melanoma Res 24: 1084-1085.
2. Afaq A, Akin O,. 2011. Imaging assessment of tumor response: past, present and future. Future Oncol 7: 669-677.
3. Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, Ravdin P, Bugarini R, et al. 2010. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 11: 55-65.
4. Alix-Panabieres C,. 2012. EPISPOT assay: detection of viable DTCs/CTCs in solid tumor patients. Recent Results Cancer Res 195: 69-76.
5. Basch E, Oliver TK, Vickers A, Thompson I, Kantoff P, Parnes H, Loblaw DA, Roth B, Williams J, Nam RK,. 2012. Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology provisional clinical opinion. J Clin Oncol 30: 3020-3025.
6. Batistatou A, Charalabopoulos A, Charalabopoulos K,. 2009. Molecular basis of metastasis. N Engl J Med 360: 1679; author reply 1679-1680.
7. Beltran H, Yelensky R, Frampton GM, Park K, Downing SR, MacDonald TY, Jarosz M, Lipson D, Tagawa ST, Nanus DM, et al. 2012. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Milan, Italy: European Urology.
8. Biankin AV, Hudson TJ,. 2011. Somatic variation and cancer: therapies lost in the mix. Hum Genet 130: 79-91.
9. Budd GT, Cristofanilli M, Ellis MJ, Stopeck A, Borden E, Miller MC, Matera J, Repollet M, Doyle GV, Terstappen LWMM, et al. 2006. Circulating tumor cells versus imaging-predicting overall survival in metastatic breast cancer. Clin Cancer Res 12: 6403-6409. (Pubitemid 44799711)
10. Butterfield LH, Potter DM, Kirkwood JM,. 2011. Multiplex serum biomarker assessments: technical and biostatistical issues. J Transl Med 9: 173-186.
11. Cohen SJ, Punt CJA, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller MC, et al. 2008. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 26: 3213-3221.
12. Collignon J, Jerusalem G,. 2012. Will targeted therapies replace chemotherapy? Rev Med Liege 67 (Spec No): 29-36.
13. Corsini LR, Bronte G, Terrasi M, Amodeo V, Fanale D, Fiorentino E, Cicero G, Bazan V, Russo A,. 2012. The role of microRNAs in cancer: diagnostic and prognostic biomarkers and targets of therapies. Expert Opin Ther Targets 16 (Suppl 2): S103-S109.
14. Coumans FAW, Doggen CJM, Attard G, de, Bono JS, Terstappen LWMM,. 2010. All circulating EpCAM + CK + CD45-objects predict overall survival in castration-resistant prostate cancer. Ann Oncol 21: 1851-1857.
15. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LWMM, et al. 2004. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351: 781-791. (Pubitemid 39095313)
16. Dabbs DJ, Klein ME, Mohsin SK, Tubbs RR, Shuai Y, Bhargava R,. 2011. High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the Oncotype DX test: an independent quality assurance study. J Clin Oncol 29: 4279-4285.
17. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LW, Pienta KJ, Raghavan D,. 2008. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14: 6302-6309.
18. Dickson MN, Tsinberg P, Tang Z, Bischoff FZ, Wilson T, Leonard EF,. 2011. Efficient capture of circulating tumor cells with a novel immunocytochemical microfluidic device. Biomicrofluidics 5:034119 (1-15).
19. Fuchs AB, Romani A, Freida D, Medoro G, Abonnenc M, Altomare L, Chartier I, Guergour D, Villiers C, Marche PN, et al. 2006. Electronic sorting and recovery of single live cells from microlitre sized samples. Lab Chip 6: 121-126.
20. Garcia-Olmo DC, Ruiz-Piqueras R, Garcia-Olmo D,. 2004. Circulating nucleic acids in plasma and serum (CNAPS) and its relation to stem cells and cancer metastasis: state of the issue. Histol Histopathol 19: 575-583. (Pubitemid 38443916)
21. Gazzaniga P, Raimondi C, Gradilone A, Naso G, Cortesi E, Frati L,. 2012. Circulating tumor cells: highlight on practical implications. Mol Diagn Ther 16: 7-11.
22. Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, Math D, Gronroos E, Martinez P, Matthews N, et al. 2012. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366: 883-892.
23. Gulyas B, Halldin C,. 2012. New PET radiopharmaceuticals beyond FDG for brain tumor imaging. Q J Nucl Med Mol Imaging 56: 173-190.
24. Gupta V, Jafferji I, Garza M, Melnikova VO, Hasegawa DK, Pethig R, Davis DW,. 2012. ApoStream™, a new dielectrophoretic device for antibody independent isolation and recovery of viable cancer cells from blood. Biomicrofluidics 6:024133 (1-14).
25. Heckman-Stoddard BM,. 2012. Oncology biomarkers: discovery, validation, and clinical use. Semin Oncol Nurs 28: 93-98.
26. Hofman VJ, Ilie MI, Bonnetaud C, Selva E, Long E, Molina T, Vignaud JM, Flejou JF, Lantuejoul S, Piaton E, et al. 2010. Cytopathologic detection of circulating tumor cells using the isolation by size of epithelial tumor cell method: promises and pitfalls. Am J Clin Pathol 135: 146-156.
27. Hou JM, Krebs M, Ward T, Sloane R, Priest L, Hughes A, Clack G, Ranson M, Blackhall F, Dive C,. 2011. Circulating tumor cells as a window on metastasis biology in lung cancer. Am J Pathol 178: 989-996.
28. Joosse SA, Hannemann J, Spotter J, Bauche A, Andreas A, Muller V, Pantel K,. 2012. Changes in keratin expression during metastatic progression of breast cancer: impact on the detection of circulating tumor cells. Clin Cancer Res 18: 993-1003.
29. Kalia M,. 2013. Personalized oncology: recent advances and future challenges. Metabolism 62 (Suppl 1): S11-S14.
30. Kalluri R, Weinberg RA,. 2009. The basics of epithelial-mesenchymal transition. J Clin Invest 119: 1420-1428.
31. Keating GM,. 2012. Pertuzumab: in the first-line treatment of HER2-positive metastatic breast cancer. Drugs 72: 353-360.
32. Larson CJ, Moreno JG, Pienta KJ, Gross S, Repollet M, O'Hara SM, Russell T, Terstappen LWMM,. 2004. Apoptosis of circulating tumor cells in prostate cancer patients. Cytometry A 62A: 46-53. (Pubitemid 39473452)
33. McNaughton-Collins MF, Barry MJ,. 2011. One man at a time-resolving the PSA controversy. N Engl J Med 365: 1951-1953.
34. Mountzios G, Sanoudou D, Syrigos KN,. 2010. Clinical pharmacogenetics in oncology: the paradigm of molecular targeted therapies. Curr Pharm Des 16: 2184-2193.
35. Nieva J, Wendel M, Luttgen MS, Marrinucci D, Bazhenova L, Kolatkar A, Santala R, Whittenberger B, Burke J, Torrey M, et al. 2012. High-definition imaging of circulating tumor cells and associated cellular events in non-small cell lung cancer patients: a longitudinal analysis. Phys Biol 9: 016004.
36. Ong FS, Das K, Wang J, Vakil H, Kuo JZ, Blackwell WL, Lim SW, Goodarzi MO, Bernstein KE, Rotter JI, et al. 2012. Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing. Expert Rev Mol Diagn 12: 593-602.
37. Pritchard CC, Kroh E, Wood B, Arroyo JD, Dougherty KJ, Miyaji MM, Tait JF, Tewari M,. 2012. Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev Res (Phila) 5: 492-497.
38. Ramaswamy S, Ross KN, Lander ES, Golub TR,. 2003. A molecular signature of metastasis in primary solid tumors. Nat Genet 33: 49-54. (Pubitemid 36068681)
39. Riethdorf S, Fritsche H, Muller V, Rau T, Schindlbeck C, Rack B, Janni W, Coith C, Beck K, Janicke F, et al. 2007. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch System. Clin Cancer Res 13: 920-928. (Pubitemid 46340368)
40. Smirnov D, Merdek K, Sprott K, Skelley A, Huang R, Tenney D, Jiang C, Milutinovi A, Tims D, Dong Y, et al. 2012. A microfluidic system for the selection of circulating tumor cells that utilizes both affinity and size capture technologies. Chicago, IL: American Association for Cancer Research.
41. Stasinopoulos I, Penet MF, Krishnamachary B, Bhujwalla ZM,. 2010. Molecular and functional imaging of invasion and metastasis: windows into the metastatic cascade. Cancer Biomark 7: 173-188.
42. Steenhuysen J,. 2012. Doctors try to make sense of cancer's genetic jumble. Chicago Tribune, June 5, 2012. http://articles.chicagotribune.com/2012- 06-05/lifestyle/sns-rt-us-cancer-genome-diagnosisbre855001-20120605-1-advances- in-understanding-cancer-genetic-mutations-clinical-oncology Accessed Sept 2012.
43. Talasaz AH, Powell AA, Huber DE, Berbee JG, Roh KH, Yu W, Xiao W, Davis MM, Pease RF, Mindrinos MN, et al. 2009. Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device. Proc Natl Acad Sci U S A 106: 3970-3975.
44. Todenhofer T, Hennenlotter J, Feverabend S, Aufderklamm S, Mischinger J, Kuhs U, Gerber V, Fetisch J, Schilling D, Hauch S, et al. 2012. Preliminary experience on the use of the Adnatest® system for detection of circulating tumor cells in prostate cancer patients. Anticancer Res 32: 3507-3513.
45. Wang D, Dafik L, Nolley R, Huang W, Wolfinger RD, Wang L-X, Peehl DM,. 2013. Anti-oligomannose antibodies as potential serum biomarkers of aggressive prostate cancer. Drug Dev Res 74: 65-80.
46. Yap TA, Gerlinger M, Futreal PA, Pusztai L, Swanton C,. 2012. Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med 4: 127ps110.
47. Zen K, Zhang CY,. 2012. Circulating microRNAs: a novel class of biomarkers to diagnose and monitor human cancers. Med Res Rev 32: 326-348.
48. Zerizer I, Al-Nahhas A, Towey D, Tait P, Ariff B, Wasan H, Hatice G, Habib N, Barwick T,. 2012. The role of early (18)F-FDG PET/CT in prediction of progression-free survival after (90)Y radioembolization: comparison with RECIST and tumour density criteria. Eur J Nucl Med Mol Imaging 39: 1391-1399.
49. Zhang T, Zhang X, Zhang X, Jiang J, Chen J, Zhou B,. 2012. Management of multiple embolization arising from atrial myxoma. Ann Thorac Surg 94: 646-649.